Excelestar Ventures

Excelestar Ventures, founded in 2010 and based in Andover, Massachusetts, is a venture capital firm that focuses on investing in companies across various stages, including seed, early, and later stages. The firm specializes in sectors such as B2B, technology, and medical industries, aiming to support businesses that require capital to expand their operations. Excelestar Ventures distinguishes itself through a hands-on management approach, working closely with portfolio companies to enhance operational efficiencies and drive sustainable growth. The firm's investment strategy involves thorough market research and consultations with industry experts to identify undervalued companies with intrinsic value. By refining and revitalizing effective business models, Excelestar seeks to create solid returns for its investors while fostering the success of its portfolio companies on a global scale.

Ibrahim Al-Qamari

Principal

Tasneem Dohadwala

Founding Partner

Emily Giudice

Principal

24 past transactions

Adona Medical

Series C in 2024
Adona Medical is a privately held company focused on innovating interventional approaches for heart failure management, a condition affecting approximately 6.5 million patients in the United States and around 26 million globally. The company develops a heart failure management system that enhances the standard of cardiac care through advanced sensor and shunt technologies. This system allows healthcare providers to personalize and tailor treatments for heart failure patients, addressing individual needs more effectively. Adona Medical's interatrial shunt technology provides valuable insights into a patient's hemodynamic status, ultimately aiming to improve care and outcomes for those suffering from this complex and progressive condition.

Brixton Biosciences

Series B in 2024
Brixton Biosciences is a clinical-stage life sciences company focused on developing innovative therapies for pain management. The company addresses significant unmet needs in both chronic and acute pain treatment, moving beyond traditional systemic approaches. Its flagship product, Neural Ice™, is a drug-free injectable therapy designed to provide safe and effective pain relief through reversible inhibition of nerve activity. This novel solution offers patients a long-lasting relief period, with effectiveness extending from thirty to sixty days following a single injection. By prioritizing non-addictive and locally targeted therapies, Brixton Biosciences aims to transform pain management practices and improve the quality of life for patients suffering from various forms of pain.

Instylla

Series C in 2023
Instylla is a medical equipment supplier based in Bedford, Massachusetts, focused on developing next-generation liquid embolics for interventional radiology. The company specializes in products designed for controlled, complete, and persistent embolization, which enhances the capabilities of healthcare professionals in various clinical applications, including peripheral hemostasis and interventional oncology. Instylla’s flagship offering, the Embrace Hydrogel Embolic System, reflects its commitment to improving patient outcomes through innovative embolization solutions.

Sealonix

Series A in 2023
Sealonix is a company dedicated to the development and commercialization of innovative hemostatic sealants utilizing proprietary biomaterials. It specializes in creating a sealant patch designed to achieve rapid hemostasis during surgical procedures, specifically targeting abdominopelvic and orthopedic operations. The PramStat patch is engineered to bioabsorb within one week of implantation, offering a timely solution for surgeons and enhancing patient safety and recovery.

Datacy

Seed Round in 2022
Datacy is a venture-backed company that specializes in providing a consumer insights data platform aimed at enhancing revenue growth for consumer packaged goods (CPG) in the digital commerce sector. The company empowers consumers by allowing them to control and monetize their personal data while offering businesses a comprehensive understanding of the factors influencing online shopping decisions. Datacy's platform features data collection, secure access, automated organization, and robust privacy measures, enabling clients to efficiently manage and analyze extensive online consumer behavior data. By connecting and interpreting billions of data points, Datacy reveals the intricate patterns and preferences that drive consumer choices, thereby offering valuable insights that facilitate strategic decision-making in digital marketing.

Adona Medical

Series B in 2022
Adona Medical is a privately held company focused on innovating interventional approaches for heart failure management, a condition affecting approximately 6.5 million patients in the United States and around 26 million globally. The company develops a heart failure management system that enhances the standard of cardiac care through advanced sensor and shunt technologies. This system allows healthcare providers to personalize and tailor treatments for heart failure patients, addressing individual needs more effectively. Adona Medical's interatrial shunt technology provides valuable insights into a patient's hemodynamic status, ultimately aiming to improve care and outcomes for those suffering from this complex and progressive condition.

Concerto Biosciences

Venture Round in 2022
Concerto Biosciences is focused on rebuilding microbial communities to enhance human health and environmental sustainability. The company has developed a pioneering ultra-high-throughput platform that allows for the experimental measurement of millions of microbial interactions, enabling the mapping of complex inter-species interaction networks. This innovative approach has led to the discovery of "ensembles," which are specific combinations of microbes that synergistically promote the healing of damaged microbial communities. By leveraging these microbial ensembles, Concerto aims to address critical challenges in various sectors, including medicine and agriculture, ultimately transforming the way humanity interacts with microbes and improving outcomes in health and food production.

Chromatic 3D Materials

Venture Round in 2021
Chromatic 3D Materials specializes in the development of advanced 3D printing materials, particularly focusing on durable elastomers suitable for finished manufactured goods. The company offers a unique additive manufacturing platform that utilizes reactive extrusion technology, enabling the production of industrial-strength rubber parts. Their innovative polyurethanes can withstand a range of mechanical stresses, such as flexing, stretching, twisting, and squeezing, making them highly adaptable and resilient. By providing customizable properties, Chromatic 3D Materials enables manufacturers to explore novel product designs while promoting sustainability and flexibility in material applications.

RoadSync

Series B in 2021
RoadSync, Inc. is a technology company that specializes in developing an online payment platform tailored for the logistics industry. Founded in 2015 and based in Atlanta, Georgia, RoadSync offers a comprehensive payment portal that facilitates instant receipts for carriers, brokers, and drivers. Its platform enhances billing management by allowing users to track all billing activities and manage recurring transaction communications. Serving a diverse clientele that includes warehouses, repair services, and tow providers, RoadSync aims to streamline logistics expense management by enabling secure and efficient payment acceptance. With a focus on modernizing commerce within the $800 billion logistics sector, RoadSync is dedicated to automating financial solutions to improve payment speed, oversight, and convenience for both payers and vendors.

Brixton Biosciences

Venture Round in 2021
Brixton Biosciences is a clinical-stage life sciences company focused on developing innovative therapies for pain management. The company addresses significant unmet needs in both chronic and acute pain treatment, moving beyond traditional systemic approaches. Its flagship product, Neural Ice™, is a drug-free injectable therapy designed to provide safe and effective pain relief through reversible inhibition of nerve activity. This novel solution offers patients a long-lasting relief period, with effectiveness extending from thirty to sixty days following a single injection. By prioritizing non-addictive and locally targeted therapies, Brixton Biosciences aims to transform pain management practices and improve the quality of life for patients suffering from various forms of pain.

Instylla

Series B in 2020
Instylla is a medical equipment supplier based in Bedford, Massachusetts, focused on developing next-generation liquid embolics for interventional radiology. The company specializes in products designed for controlled, complete, and persistent embolization, which enhances the capabilities of healthcare professionals in various clinical applications, including peripheral hemostasis and interventional oncology. Instylla’s flagship offering, the Embrace Hydrogel Embolic System, reflects its commitment to improving patient outcomes through innovative embolization solutions.

Terecircuits

Venture Round in 2020
Terecircuits Corporation is a materials and processes developer focused on micro assembly and mass transfer for displays and advanced electronics. Established in 2015 and based in Mountain View, California, the company specializes in advanced polymers, encapsulation materials, and liquid metal interconnects. Terecircuits is known for its innovative photo-polymer mass transfer techniques, particularly for MicroLED applications in automotive and augmented/virtual reality environments. Additionally, the company designs new materials and methodologies for systems in package manufacturing, catering to the Internet of Things and health technology sectors. By offering novel circuit fabrication and assembly techniques, Terecircuits enables industries such as displays, electronics, and semiconductors to create products that are lighter, more efficient, and cost-effective.

Adona Medical

Series A in 2020
Adona Medical is a privately held company focused on innovating interventional approaches for heart failure management, a condition affecting approximately 6.5 million patients in the United States and around 26 million globally. The company develops a heart failure management system that enhances the standard of cardiac care through advanced sensor and shunt technologies. This system allows healthcare providers to personalize and tailor treatments for heart failure patients, addressing individual needs more effectively. Adona Medical's interatrial shunt technology provides valuable insights into a patient's hemodynamic status, ultimately aiming to improve care and outcomes for those suffering from this complex and progressive condition.

Kinnos

Series A in 2020
Kinnos Inc. is a biotechnology company based in Brooklyn, New York, that specializes in innovative color technology to enhance disinfection practices. Founded in 2014, the company manufactures Highlight, a patent-pending powdered additive that improves the visibility of disinfectants, thereby increasing user compliance and ensuring thorough cleaning. Highlight provides real-time color-change feedback, empowering individuals to disinfect surfaces with confidence. In addition to the Highlight additive, Kinnos offers Highlight Wipes, a dispensing machine for wipes, and Highlight Powder, a disinfectant additive. The company's mission is to transform how disinfectants are used, ultimately aiming to prevent disease outbreaks and promote public health through visible disinfection.

Kinnos

Venture Round in 2020
Kinnos Inc. is a biotechnology company based in Brooklyn, New York, that specializes in innovative color technology to enhance disinfection practices. Founded in 2014, the company manufactures Highlight, a patent-pending powdered additive that improves the visibility of disinfectants, thereby increasing user compliance and ensuring thorough cleaning. Highlight provides real-time color-change feedback, empowering individuals to disinfect surfaces with confidence. In addition to the Highlight additive, Kinnos offers Highlight Wipes, a dispensing machine for wipes, and Highlight Powder, a disinfectant additive. The company's mission is to transform how disinfectants are used, ultimately aiming to prevent disease outbreaks and promote public health through visible disinfection.

Conformal Medical

Series B in 2018
Conformal Medical, Inc., established in 2016 and based in Nashua, New Hampshire, specializes in developing medical devices aimed at preventing stroke in patients with atrial fibrillation (AFib). The company's primary product is the CLAAS Technology, a solution designed to seal the left atrial appendage (LAA) in AFib patients. This technology forms part of their conformal left atrial appendage closure (LAAC) system.

Lantos

Venture Round in 2018
Lantos Technologies, Inc., established in 2009 and headquartered in Derry, New Hampshire, specializes in developing advanced 3D digital ear scanning technology. The company offers the FDA-cleared AURA system, which captures comprehensive data from the outer ear to deep within the ear canal, enabling designers to create personalized in-ear devices with superior comfort and sound quality. This includes custom in-ear headphones, musicians' monitors, hearing aids, and noise protection solutions. Lantos' technology enhances clinical efficiency for audiologists by providing precise measurements, improving patient outcomes, and streamlining the process for faster turnaround times on custom devices.

Diesel Labs

Seed Round in 2018
Diesel Labs, founded in 2016 and based in Boston, Massachusetts, operates as a content intelligence company. It specializes in measuring audience attention across various entertainment platforms such as Twitter, YouTube, TikTok, Facebook, and Instagram. By analyzing the engagement of millions of users with content on these platforms, Diesel Labs helps media companies make informed decisions about content creation, distribution, and measurement strategies to enhance audience engagement and subscribership.

Altiostar

Venture Round in 2017
Altiostar Networks, Inc., established in 2011 and headquartered in Tewksbury, Massachusetts, specializes in designing and developing outdoor coverage and capacity solutions for the LTE market. The company offers macro iRRH radios, suitable for various outdoor environments and mountable on cell towers, masts, or building walls. Additionally, they provide small cell iRRHs, designed to maximize network capacity in high user-density urban zones and address network coverage gaps. Altiostar serves mobile network operators, aiming to enhance communication experiences while reducing technology costs. The company's innovative, experienced team focuses on disaggregated, multi-vendor, cloud-native mobile network solutions to enable efficient and cost-effective LTE network deployment and expansion.

Anova Data

Series B in 2015
Anova Data, established in 2015 and based in Westford, Massachusetts, specializes in comprehensive analytics solutions for telecommunications networks. The company offers an end-to-end analytics framework that empowers network operators to proactively manage their systems by unlocking the full potential of subscriber and network data insights. Anova's software suite covers various operational functions such as marketing, monetization, customer care, network assurance, and service orchestration, enabling operators to effectively navigate unprecedented subscriber data growth and regain control over their networks.

SpaceOAR

Series D in 2014
SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Zettics

Series D in 2013
Zettics is a provider of mobile analytics and measurement applications, specializing in delivering comprehensive insights into data usage for telecommunications operators. The company offers a robust monitoring and analytics tool that enhances real-time visibility across various applications, including video and messaging. By enabling operators to better understand subscriber behavior and trends, Zettics helps them extract greater value from their customer relationships while ensuring compliance with privacy policies. Its solutions support over 60 use cases, allowing operators to monetize data with third parties, enrich customer relationship management systems, identify network abuse, analyze pricing plans, enhance advertising strategies, reduce churn, and forecast network usage growth. Overall, Zettics empowers telecommunications operators to optimize their networks and improve their service offerings, resulting in a significant return on investment.

nVision Medical

Series A in 2013
nVision Medical Corporation is a privately-held medical device company based in Saratoga, California, focused on advancing women's health innovation. Established in 2009, the company specializes in developing devices to assess and treat female infertility resulting from fallopian tube dysfunction. nVision's products are designed not only to detect conditions such as ovarian cancer and tube blockage but also to address the challenges faced in diagnosing and treating issues within the female reproductive tract. By concentrating on these critical areas, nVision aims to improve clinical outcomes and enhance the overall health of women. As of 2018, nVision Medical operates as a subsidiary of Boston Scientific Corporation.

Sera Prognostics

Series A in 2011
Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, specializing in women's health diagnostics. Founded in 2008, it focuses on developing innovative diagnostic tests that aid in the early prediction of a woman's individualized risk for complications during pregnancy, including premature birth, preeclampsia, and gestational diabetes. Sera's proprietary proteomics and bioinformatics platform enables the discovery and commercialization of blood-based biomarker tests, which provide critical information to healthcare providers. Notably, the company's PreTRM® Test assesses the risk of spontaneous premature delivery, facilitating timely interventions for at-risk patients. By addressing the healthcare challenges associated with pregnancy complications, Sera aims to enhance maternal and neonatal health while reducing overall healthcare costs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.